Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy.

Trial Profile

Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Carbamazepine (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Lundbeck Inc
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 20 Sep 2011 Planned end date changed from 1 Sep 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top